1. Short title This Act may be cited as the Securing Gene Synthesis Act . 2. Requirements for the dissemination of synthetic genetic material Section 351A of the Public Health Service Act ( 42 U.S.C. 262a ) is amended— (1) in subsection (b)(2), by striking the semicolon at the end and inserting the following: , including by— (A) assessing uncertainties, risks, costs, and benefits associated with the implementation of different types of protocols or other regulations to reduce the risk of potential misuse of de novo gene synthesis products; (B) determining the types of protocols or other regulations that could detect the potential misuse of de novo gene synthesis products while generating benefits that are larger than their costs; (C) requiring gene synthesis providers or manufacturers of gene synthesis equipment to implement screening protocols to detect misuse of de novo gene synthesis products; (D) verifying or provisionally verifying that gene synthesis providers and manufacturers of gene synthesis equipment adhere to the regulation prescribed pursuant to subparagraph (C); (E) assessing, collecting, and waiving fees for enforcing the regulation prescribed pursuant to subparagraph (C); and (F) requiring any entity receiving Federal funds, or any Federal agency, which purchases de novo gene synthesis products from a gene synthesis provider or gene synthesis equipment from a manufacturer of gene synthesis equipment to purchase such products and equipment only if such providers or manufacturers are verified or provisionally verified pursuant to subparagraph (D); ; (2) in subsection (e)(1), by striking the period at the end and inserting , including through the revocation of Federal research funding for any entity found to be in violation of subsection (b)(2)(E), or through the withholding of such funding for such an entity until the entity demonstrates compliance with such subsection.